443 related articles for article (PubMed ID: 34088875)
1. Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
Maggi P; Kuhle J; Schädelin S; van der Meer F; Weigel M; Galbusera R; Mathias A; Lu PJ; Rahmanzadeh R; Benkert P; La Rosa F; Bach Cuadra M; Sati P; Théaudin M; Pot C; van Pesch V; Leppert D; Stadelmann C; Kappos L; Du Pasquier R; Reich DS; Absinta M; Granziera C
Neurology; 2021 Aug; 97(6):e543-e553. PubMed ID: 34088875
[TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
[TBL] [Abstract][Full Text] [Related]
3. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
[TBL] [Abstract][Full Text] [Related]
4. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA
Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580
[TBL] [Abstract][Full Text] [Related]
5. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis.
Rosso M; Gonzalez CT; Healy BC; Saxena S; Paul A; Bjornevik K; Kuhle J; Benkert P; Leppert D; Guttmann C; Bakshi R; Weiner HL; Chitnis T
Ann Clin Transl Neurol; 2020 Jun; 7(6):945-955. PubMed ID: 32452160
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
[TBL] [Abstract][Full Text] [Related]
7. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.
Jakimovski D; Kuhle J; Ramanathan M; Barro C; Tomic D; Hagemeier J; Kropshofer H; Bergsland N; Leppert D; Dwyer MG; Michalak Z; Benedict RHB; Weinstock-Guttman B; Zivadinov R
Ann Clin Transl Neurol; 2019 Sep; 6(9):1757-1770. PubMed ID: 31437387
[TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
Fujimori J; Nakashima I
J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375
[TBL] [Abstract][Full Text] [Related]
9. MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis.
Rosso M; Healy BC; Saxena S; Paul A; Bjornevik K; Kuhle J; Benkert P; Leppert D; Guttmann C; Bakshi R; Weiner HL; Chitnis T
J Neuroimaging; 2021 Mar; 31(2):388-393. PubMed ID: 33476489
[TBL] [Abstract][Full Text] [Related]
10. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
[TBL] [Abstract][Full Text] [Related]
11. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.
Reinert MC; Benkert P; Wuerfel J; Michalak Z; Ruberte E; Barro C; Huppke P; Stark W; Kropshofer H; Tomic D; Leppert D; Kuhle J; Brück W; Gärtner J
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32404429
[TBL] [Abstract][Full Text] [Related]
12. Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
Srpova B; Uher T; Hrnciarova T; Barro C; Andelova M; Michalak Z; Vaneckova M; Krasensky J; Noskova L; Havrdova EK; Kuhle J; Horakova D
Mult Scler; 2021 Jan; 27(1):52-60. PubMed ID: 31961243
[TBL] [Abstract][Full Text] [Related]
13. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort.
Steffen F; Uphaus T; Ripfel N; Fleischer V; Schraad M; Gonzalez-Escamilla G; Engel S; Groppa S; Zipp F; Bittner S
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411080
[TBL] [Abstract][Full Text] [Related]
14. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
[TBL] [Abstract][Full Text] [Related]
15. Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS.
Aktas O; Renner A; Huss A; Filser M; Baetge S; Stute N; Gasis M; Lepka K; Goebels N; Senel M; Graf J; Enzinger C; Pinter D; Antoch G; Turowski B; Hartung HP; Albrecht P; Otto M; Tumani H; Penner IK
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32972970
[TBL] [Abstract][Full Text] [Related]
16. Quantitative susceptibility mapping of the normal-appearing white matter as a potential new marker of disability progression in multiple sclerosis.
Pietroboni AM; Colombi A; Contarino VE; Russo FML; Conte G; Morabito A; Siggillino S; Carandini T; Fenoglio C; Arighi A; De Riz MA; Arcaro M; Sacchi L; Fumagalli GG; Bianchi AM; Triulzi F; Scarpini E; Galimberti D
Eur Radiol; 2023 Aug; 33(8):5368-5377. PubMed ID: 36562783
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
[TBL] [Abstract][Full Text] [Related]
18. Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3.
Peng Y; Zhang Y; Chen Z; Peng H; Wan N; Zhang J; Tang J; Wang P; Xie Y; Cai Q; Liu S; Zhang X; Wang C; Yuan H; Li T; Wan L; Shi Y; Qiu R; Klockgether T; Tang B; Liao W; Jiang H
Neurology; 2020 Dec; 95(22):e2977-e2987. PubMed ID: 32817181
[TBL] [Abstract][Full Text] [Related]
19. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
Barro C; Healy BC; Liu Y; Saxena S; Paul A; Polgar-Turcsanyi M; Guttmann CRG; Bakshi R; Kropshofer H; Weiner HL; Chitnis T
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36376097
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
Huppke B; Reinert MC; Hummel-Abmeier H; Stark W; Gärtner J; Huppke P
Neurology; 2023 Nov; 101(19):e1873-e1883. PubMed ID: 37748882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
